Project Grant R44CA306595
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10014, USA
Similar Awards
- The National Cancer Institute awarded $400,000 to Intra Therapeutics, Inc. on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop IT-001, a localized cancer immunotherapy for intratumoral injection. IT-001 combines interleukin-12 (IL-12) with a proprietary injectable hydrogel designed to retain the cytokine within tumors for up to four weeks while minimizing systemic toxicity. Preclinical data demonstrate that a single IT-001 treatment produces complete...
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Cancer Institute awarded Ramona Optics Inc. $306,872 on September 9, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a multi-camera array scanner (MCAS) that rapidly digitizes and automatically analyzes fine-needle aspiration (FNA) cytology smears in three dimensions. The MCAS system will provide real-time imaging to enable rapid on-site evaluation (ROSE) of FNA biopsy specimens during procedures such as bronchoscopies. Current limitations in ROSE...
- The National Cancer Institute awarded Nanocan Therapeutics Corporation $2,996,343 on September 24, 2025, to conduct the first clinical trial of the Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel for treatment of advanced cervical cancer under the Cancer Treatment Research program (CFDA 93.395). The LIFE gel is a biocompatible, biodegradable immunotherapeutic administered locally in conjunction with hypo-fractionated radiotherapy. The technology extends local radiotherapy's use from...
- The National Cancer Institute awarded Rush River Research Corporation $610,080 on September 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel thermoelectric scalp cooling device for mitigating chemotherapy-induced alopecia. The award funds development of a next-generation scalp cooling cap using solid-state thermoelectric cooling technology. The device is designed as a fluid-free, fully portable system that delivers precise, sustained cooling...
- The National Cancer Institute awarded Northeastern University $1,144,692 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for precision cancer microsurgery using laser ablation-cooling with pulse bursts. The project develops a novel handheld microsurgical device that integrates video cellular-resolution microendoscopy with high-speed pulsed laser ablation to enable rapid visualization and eradication of microscopic tumor deposits at surgical margins...
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded $1,008,660 to Aim Medical Robotics Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a commercial-grade MRI-compatible neurosurgical robotic system for minimally invasive laser interstitial thermal therapy (LITT) treatment of brain tumors. Aim Medical Robotics is refining and validating the AIM Robotic System, a compact robotic platform designed to complete the full LITT workflow...
- The National Cancer Institute awarded Tiba Biotech LLC $399,300 on September 10, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted delivery of enhanced self-amplifying RNA encoding tumor antigens to the spleen for cancer immunotherapy. Tiba Biotech will combine proprietary enhanced self-amplifying RNA (esRNA) technology with spleen-targeting biodegradable nanoparticles based on molecularly defined dendritic structures to deliver tumor antigen to...